Stephen S Whitehead

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Prospects for a dengue virus vaccine
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 5:518-28. 2007
  2. pmc A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys
    R S Bennett
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    J Virol 86:420-6. 2012
  3. pmc Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus
    Kathryn A Hanley
    Department of Biology, New Mexico State University, Las Cruces, NM 88003, USA
    BMC Ecol 8:1. 2008
  4. pmc A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1653-7. 2003
  5. ncbi request reprint Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 6515, Building 50, 50 South Drive, Bethesda, MD 20892 8007, USA
    Vaccine 21:4307-16. 2003
  6. pmc Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
    BMC Infect Dis 4:39. 2004
  7. ncbi request reprint Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity
    Kathryn A Hanley
    Laboratory of Infectious Diseases LID, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 22:3440-8. 2004
  8. pmc Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3203, USA
    Vaccine 26:4150-9. 2008
  9. pmc Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:23. 2007
  10. ncbi request reprint Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 21:4317-27. 2003

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Prospects for a dengue virus vaccine
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 5:518-28. 2007
    ..In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future...
  2. pmc A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys
    R S Bennett
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    J Virol 86:420-6. 2012
    ..Generation of highly attenuated yet immunogenic chimeric bunyaviruses could be an efficient general method for development of vaccines effective against these pathogenic viruses...
  3. pmc Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus
    Kathryn A Hanley
    Department of Biology, New Mexico State University, Las Cruces, NM 88003, USA
    BMC Ecol 8:1. 2008
    ..Here we tested the hypothesis that differences between the invasive and native strain in their infectivity for Aedes aegypti mosquitoes, the primary vector of DENV, contributed to the competitive success of the invasive strain..
  4. pmc A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1653-7. 2003
    ..The ability of the Delta30 mutation to attenuate both DEN1 and DEN4 viruses suggests that a tetravalent DEN vaccine could be generated by introduction of the Delta30 mutation into wt DEN viruses belonging to each of the four serotypes...
  5. ncbi request reprint Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 6515, Building 50, 50 South Drive, Bethesda, MD 20892 8007, USA
    Vaccine 21:4307-16. 2003
    ....
  6. pmc Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
    BMC Infect Dis 4:39. 2004
    ..To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate...
  7. ncbi request reprint Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity
    Kathryn A Hanley
    Laboratory of Infectious Diseases LID, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 22:3440-8. 2004
    ..The application of these attenuating mutations to flavivirus vaccine development is discussed...
  8. pmc Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3203, USA
    Vaccine 26:4150-9. 2008
    ..These viruses may be considered for use as SLE vaccine candidates and for use as diagnostic reagents with reduced virulence...
  9. pmc Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:23. 2007
    ....
  10. ncbi request reprint Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 21:4317-27. 2003
    ..The importance of these Vero cell adaptation mutations in flavivirus vaccine design and development is discussed...
  11. ncbi request reprint Genetically modified, live attenuated dengue virus type 3 vaccine candidates
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Am J Trop Med Hyg 71:811-21. 2004
    ..Thus, the rDEN3/4(ME) and rDEN3/4Delta30(ME) antigenic chimeric viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine...
  12. pmc La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 5:25. 2008
    ..As an initial step in the establishment of useful animal models to support vaccine development, we examined LACV infectivity, pathogenesis, and immunogenicity in both weanling mice and rhesus monkeys...
  13. pmc Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
    Vaccine 26:817-28. 2008
    ..In addition, rDEN3Delta30/31 had reduced replication in Toxorynchites mosquitoes following intrathoracic inoculation. The results are discussed in the context of vaccine development and the physical structure of the DENV 3'-UTR...
  14. ncbi request reprint A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 312:222-32. 2003
    ..The opposing effects of the NS4B P101L mutation in mosquito and vertebrate systems suggest that the NS4B protein is involved in maintaining the balance between efficient replication in the mosquito vector and the human host...
  15. pmc Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 4:41. 2007
    ..The majority of LACV infections are mild and never reported, however, serologic studies estimate infection rates of 10-30/100,000 in endemic areas...
  16. pmc Targeted mutagenesis as a rational approach to dengue virus vaccine development
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892 3203, USA
    Curr Top Microbiol Immunol 338:145-58. 2010
    ..Clinical studies of rDEN4Delta30-4995 are ongoing...
  17. pmc Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation
    Camilo Ansarah-Sobrinho
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD, USA
    Virology 381:67-74. 2008
    ..Optimized production approaches allow the production of DENV RVPs with titers suitable for the study of DENV entry, assembly, and the analysis of the humoral immune response of infected and vaccinated individuals...
  18. pmc Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 79:5516-28. 2005
    ..However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials...
  19. ncbi request reprint Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Virology 300:125-39. 2002
    ....
  20. ncbi request reprint Development of a live attenuated dengue virus vaccine using reverse genetics
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892 8133, USA
    Viral Immunol 19:10-32. 2006
    ..The level of attenuation of each dengue vaccine component can be increased, if needed, by introduction of additional attenuating mutations that have been well characterized...
  21. pmc A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus
    Tsai Yu Lin
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:3501-12. 2012
    ..Together, we have developed a simple and rapid approach to produce infectious WNV that accelerates the process of manipulating the genome to study the structure and function of the structural genes of this important human pathogen...
  22. pmc Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:135. 2011
    ..Human infections are frequent with neutralizing antibodies present in 60-80% of the elderly population in endemic areas...
  23. pmc The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys
    Richard S Bennett
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virol J 8:136. 2011
    ..The virus is genetically similar to Inkoo virus circulating in Europe, suggesting that much of the northern hemisphere contains JCV or similar variants...
  24. pmc A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus
    Kimberly A Dowd
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1002111. 2011
    ....
  25. pmc Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes
    Kathryn A Hanley
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:525-31. 2002
    ..This large set of charge-to-alanine mutations specifying a wide range of attenuation for mouse brain should prove useful in fine-tuning recombinant live attenuated DEN vaccines...
  26. pmc Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization
    Steevenson Nelson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 4:e1000060. 2008
    ..Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV...
  27. pmc Dengue research opportunities in the Americas
    Catherine A Laughlin
    Virology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 6603, USA
    J Infect Dis 206:1121-7. 2012
    ..Although dengue is a major global tropical pathogen, epidemiologic and disease control considerations in this article emphasize dengue in the Americas...
  28. doi request reprint Immune response to dengue virus and prospects for a vaccine
    Brian R Murphy
    Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 29:587-619. 2011
    ..Vaccines will need to provide long-term protection against each of the four DENV serotypes by inducing neutralizing antibodies, and live, attenuated and various nonliving virus vaccines are in development...
  29. ncbi request reprint rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  30. ncbi request reprint The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Hum Vaccin 2:167-73. 2006
    ..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial...
  31. ncbi request reprint rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Hum Vaccin 2:255-60. 2006
    ..The Delta30 mutation remained unchanged in each isolate, confirming the stability of the Delta30 mutation. Further evaluation of this vaccine in a tetravalent formulation is warranted...
  32. pmc Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers
    Peter F Wright
    Department of Pediatrics, Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA
    Vaccine 26:882-90. 2008
    ..To provide a sufficient level of immunity to widely prevalent, highly neurovirulent strains of TBEV in humans, vaccine candidates will likely need to be based on the TBEV structural protein genes...
  33. pmc Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains
    Nikos Vasilakis
    Center for Biodefense and Emerging Infectious Diseases and Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555 0609, USA
    Virology 377:296-307. 2008
    ..Understanding the genetic relationships and phenotypic differences between endemic and sylvatic DENV genotypes may provide valuable insight into DENV emergence and guide monitoring of future outbreaks...
  34. ncbi request reprint Arguments for live flavivirus vaccines
    Brian R Murphy
    Lancet 364:499-500. 2004